杰龙 GERN 深 沪
交易中 07-07 10:10:17 美东时间
1.45
+0.010
+0.69%
华盛通- 最 高1.465
- 今 开1.44
- 成交量 90.40万股
- 最 低 1.44
- 昨 收 1.44
- 总市值 9.30亿
- 52周最高 2.01
- 市盈率 静 --
- 换手率 0.14%
- 52周最低 1.04
- 委 比 20.83%
- 总股本 6.42亿
- 历史最高 7.79
- 量 比 1.20
- 振 幅 1.74%
- 历史最低 0.75
- 每 手 1
- 风险率 0.17%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多主题圆桌：生命的新算法，AI重构医疗产业全链路｜36氪WAVES2026新浪潮
“2026年，创投圈的浪潮再次翻涌：AI从技术概念走进产业深水区，硬科技创业从“小众赛道” 变成“主流共识”，年轻的创业者们正在用代码和双手，重新定义中国创新的...
06-24 15:31
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation granted stock options to purchase 690,000 shares to eight new employees. The options, priced at $1.23 per share, vest over four years with 12.5% after six months and the rest in equal monthly installments. The awards were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4) and the 2018 Inducement Award Plan. Geron is a biopharmaceutical company focused on treating blood cancers, with its lead product, RYT...
06-18 20:01
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>Geron Corporation granted stock options to five new employees on May 15, 2026, totaling 333,750 shares. The options have an exercise price of $1.29 per share, a ten-year term, and vest over four years. The first 12.5% vests after six months of employment, with the remaining shares vesting in equal installments over the next 42 months. The awards were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4) and the 2018 Induc...
05-18 20:01
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
Geron Reports Q1 2026 Results: Full Earnings Call Transcript
On Wednesday, Geron (NASDAQ:GERN) discussed first-quarter financial results dur...
05-06 20:51
Geron posts corporate presentation outlining RYTELO commercial strategy, growth plans
Geron posts corporate presentation outlining RYTELO commercial strategy, growth plans Geron reaffirmed 2026 guidance for RYTELO net product revenue of $220 million-$240 million. Total operating expenses expected at $230 million-$240 million. Q1 2026 RYTELO net revenue reported at $51.8 million, up 3
05-06 20:50
Geron Q1 EPS $(0.01) Beats $(0.02) Estimate, Sales $51.771M Beat $50.582M Estimate
Geron (NASDAQ:GERN) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.02) by 50 percent. This is a 66.67 percent increase over losses of $(0.03) per share from the same
05-06 19:07
Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights
Geron Corporation reported Q1 2026 financial results, with RYTELO® (imetelstat) net product revenue of $51.8 million, an 8% increase from Q4 2025. The company reaffirmed its 2026 financial guidance, expecting net product revenue of $220-$240 million and total operating expenses of $230-$240 million. Geron strengthened its leadership team with new appointments and ended Q1 2026 with $341 million in cash and marketable securities. The company also ...
05-06 11:00
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation granted Timothy Williams, its new Executive Vice President, Chief Legal Officer, and Corporate Secretary, an equity award of 2,500,000 stock options. The options, priced at $1.73 per share, vest over four years with 12.5% after six months and the rest in equal installments over the next 42 months. The grant was approved by Geron's Compensation Committee under Nasdaq Listing Rule 5635(c)(4) and the 2018 Inducement Award Plan.
04-14 20:05
Fastenal, Replimune Group, Children's Place And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures lower, with Dow futures down 150 points. Fastenal shares dip 4% after meeting earnings estimate. Other stocks also down.
04-13 20:02
